Corrigendum to "2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists" [Bioorg. Med. Chem. Lett. 18 (2008) 2103-2108] (DOI:10.1016/j.bmcl.2008.01.090);2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 6, 2008, Pages 2103-2108

  Shireman, Brock T ^a   Dvorak, Curt A ^a   Rudolph, Dale A ^a   Bonaventure, Pascal ^a   Nepomuceno, Diane ^a   Dvorak, Lisa ^a   Miller, Kirsten L ^a   Lovenberg, Timothy W ^a   Carruthers, Nicholas I ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

5 HT; 5 HT2A; 5 HT2B; 5 HT2C; Serotonin

Indexed keywords

AZEPINE DERIVATIVE; FLUORINE; NITROGEN; PHENYL GROUP; PYRIMIDINE DERIVATIVE; SEROTONIN 2A ANTAGONIST; TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVE; TETRAHYDROPYRIMIDOAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; REACTION ANALYSIS; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

EID: 40749138982     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.111     Document Type: Erratum

References (22)

1. Hoyer D., Hannon J.P., and Martin G.R. Pharmacol. Biochem. Behav. 71 (2002) 533
2. Hoyer D., and Martin G.R. Behav. Brain Res. 73 (1996) 263
3. Raymond J.R., Mukhin Y.V., Gelasco A., Turner J., Collinsworth G., Gettys T.W., Grewal J.S., and Garnovskayam M.N. Pharmacol. Ther. 92 (2001) 179
4. Thompson A.J., and Lummis S.C.R. Curr. Pharm. Des. 12 (2006) 3615
5. Roth B.L., Lopez E., Patil S., and Kroeze W.K. Neuroscientist 6 (2000) 252
6. 2A receptor, see:. Leyson J.E. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 11
7. Stefanski R., and Goldberg S.R. CNS Drugs 7 (1997) 388
8. Dugovic C. J. Sleep. Res. 1 (1992) 163
9. Sharpley A.L., Elliott J.M., Attenburrow M.-J., and Cowen P.J. Neuropharmacology 33 (1994) 467
10. Rinaldi-Carmona M., Congy C., Santucci V., Simiano J., Gautret B., Neliat G., Labbeeuw B., Le Fur G., Soubrie P., and Breliere J.C. J. Pharmacol. Exp. Ther. 262 (1992) 759
11. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., Frank R.A., Van Giersbergen P.L.M., McCloskey T.C., Johnson M.P., McCarthy D.R., Poirot M., Senyah Y., Siegel B.W., and Widmaier C. J. Pharmacol. Exp. Ther. 277 (1992) 968
12. Fish L.R., Gilligan M.T., Humphries A.C., Ivarsson M., Ladduwahetty T., Merchant K.J., O'Connor D., Patel S., Philipps E., Vargas H.M., Hutson P.H., and MacLeod A.M. Bioorg. Med. Chem. Lett. 15 (2005) 3665
13. Fletcher S.R., Burkamp F., Blurton P., Cheng S.K.F., Clarkson R., O'Connor D., Spinks D., Tudge M., van Niel M.B., Patel S., Chapman K., Marwood R., Shepheard S., Bentley G., Cook G.P., Bristow L.J., Castro J.L., Hutson P.H., and MacLeod A.M. J. Med. Chem. 45 (2002) 492
14. Sanfilippo P.J., Urbanski M., Williams L., Press J.B., Katz L.B., Shriver D.A., Fernandez J.A., Shatynski D., and Offord S.J. Eur. J. Med. Chem. 27 (1992) 655
15. 2 chromatography (5-30% EtOAc/hexanes) to give 16, 17, or 31-33.
16. Dvorak C.A., Rudolph D.A., Ma S., and Carruthers N.I. J. Org. Chem. 70 (2005) 4188
17. Moriya T., Oki T., Yamaguchi S., Morosawa S., and Yokoo A. Bull. Chem. Soc. JpN. 41 (1968) 230
18. Roglans A., Marquet J., and Moreno-Manas M. Syn. Comm. 22 (1992) 1249
19. Lotte B., Krogsgaard-Larsen P., Schaumburg K., Johansen J.S., Falch E., and Curtis D.R. J. Med. Chem. 29 (1986) 224
20. Bonaventure P., Nepomuceno D., Miller K., Chen J., Kuei C., Kamme F., Tran D., Lovenberg T.W., and Liu C. Eur. J. Pharmacol. 513 (2005) 181
21. 2C.
22. 2C).